135 related articles for article (PubMed ID: 17330838)
1. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
[TBL] [Abstract][Full Text] [Related]
2. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Garcia AA; Sill MW; Lankes HA; Godwin AK; Mannel RS; Armstrong DK; Carolla RL; Liepman MK; Spirtos NM; Fischer EG; Leslie KK
Gynecol Oncol; 2012 Mar; 124(3):569-74. PubMed ID: 22037316
[TBL] [Abstract][Full Text] [Related]
3. EGFR/HER-targeted therapeutics in ovarian cancer.
Wilken JA; Badri T; Cross S; Raji R; Santin AD; Schwartz P; Branscum AJ; Baron AT; Sakhitab AI; Maihle NJ
Future Med Chem; 2012 Mar; 4(4):447-69. PubMed ID: 22416774
[TBL] [Abstract][Full Text] [Related]
4. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Mabuchi S; Sugiyama T; Kimura T
J Gynecol Oncol; 2016 May; 27(3):e31. PubMed ID: 27029752
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer relies on the PDGFRβ-fibronectin axis for tumorsphere formation and metastatic spread.
Gendrau-Sanclemente N; Figueras A; Gracova K; Lahiguera Á; Alsina-Sanchís E; Marín-Jiménez JA; Vidal A; Matias-Guiu X; Fernandez-Gonzalez S; Barahona M; Martí L; Ponce J; Viñals F
Mol Oncol; 2024 Jan; 18(1):136-155. PubMed ID: 38010623
[TBL] [Abstract][Full Text] [Related]
6. Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer.
Lu W; Xie B; Tan G; Dai W; Ren J; Pervaz S; Li K; Li F; Wang Y; Wang M
Front Endocrinol (Lausanne); 2023; 14():1088944. PubMed ID: 36742380
[TBL] [Abstract][Full Text] [Related]
7. Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response.
Rickard BP; Conrad C; Sorrin AJ; Ruhi MK; Reader JC; Huang SA; Franco W; Scarcelli G; Polacheck WJ; Roque DM; Del Carmen MG; Huang HC; Demirci U; Rizvi I
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503128
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
Parashar D; Nair B; Geethadevi A; George J; Nair A; Tsaih SW; Kadamberi IP; Gopinadhan Nair GK; Lu Y; Ramchandran R; Uyar DS; Rader JS; Ram PT; Mills GB; Pradeep S; Chaluvally-Raghavan P
Cancer Res; 2020 Dec; 80(24):5554-5568. PubMed ID: 33087324
[TBL] [Abstract][Full Text] [Related]
9. Flow-induced Shear Stress Confers Resistance to Carboplatin in an Adherent Three-Dimensional Model for Ovarian Cancer: A Role for EGFR-Targeted Photoimmunotherapy Informed by Physical Stress.
Nath S; Pigula M; Khan AP; Hanna W; Ruhi MK; Dehkordy FM; Pushpavanam K; Rege K; Moore K; Tsujita Y; Conrad C; Inci F; Carmen MGD; Franco W; Celli JP; Demirci U; Hasan T; Huang HC; Rizvi I
J Clin Med; 2020 Mar; 9(4):. PubMed ID: 32231055
[TBL] [Abstract][Full Text] [Related]
10. STAT3 signaling in ovarian cancer: a potential therapeutic target.
Liang R; Chen X; Chen L; Wan F; Chen K; Sun Y; Zhu X
J Cancer; 2020; 11(4):837-848. PubMed ID: 31949487
[TBL] [Abstract][Full Text] [Related]
11. Kinase Inhibitors and Ovarian Cancer.
Katopodis P; Chudasama D; Wander G; Sales L; Kumar J; Pandhal M; Anikin V; Chatterjee J; Hall M; Karteris E
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547471
[TBL] [Abstract][Full Text] [Related]
12. EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells.
Mallmann-Gottschalk N; Sax Y; Kimmig R; Lang S; Brandau S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546690
[TBL] [Abstract][Full Text] [Related]
13. A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.
Hu CW; Qiu Y; Ligeralde A; Raybon AY; Yoo SY; Coombes KR; Qutub AA; Kornblau SM
Nat Biomed Eng; 2019 Nov; 3(11):889-901. PubMed ID: 30988472
[TBL] [Abstract][Full Text] [Related]
14. EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors.
Cîrstea AE; Stepan AE; Zăvoi RE; Simionescu CE
Curr Health Sci J; 2018; 44(2):129-134. PubMed ID: 30746159
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910
[TBL] [Abstract][Full Text] [Related]
16. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
[No Abstract] [Full Text] [Related]
17. Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.
Liu Z; Gao W
Toxicol Appl Pharmacol; 2017 Nov; 335():16-27. PubMed ID: 28942004
[TBL] [Abstract][Full Text] [Related]
18. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.
Mehner C; Oberg AL; Goergen KM; Kalli KR; Maurer MJ; Nassar A; Goode EL; Keeney GL; Jatoi A; Radisky DC; Radisky ES
Genes Cancer; 2017 May; 8(5-6):589-599. PubMed ID: 28740577
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistance and targeted therapies in ovarian and endometrial cancers.
Brasseur K; Gévry N; Asselin E
Oncotarget; 2017 Jan; 8(3):4008-4042. PubMed ID: 28008141
[TBL] [Abstract][Full Text] [Related]
20. The rise of genomic profiling in ovarian cancer.
Previs RA; Sood AK; Mills GB; Westin SN
Expert Rev Mol Diagn; 2016 Dec; 16(12):1337-1351. PubMed ID: 27828713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
